Precision oncology in head and neck cancers: From molecular mechanisms to novel therapeutic strategies

Neck neoplasms encompass a diverse group of malignancies, including head and neck squamous cell carcinoma (HNSCC), thyroid cancer, salivary gland tumors, and lymphomas. Recent advancements in molecular biology and immunotherapy have revolutionized the treatment landscape for these cancers. Personalized medicine, guided by genomic profiling and biomarker-driven therapies, has emerged as a promising approach to improve patient outcomes. In HNSCC, targeted therapies focusing on epidermal growth factor receptor (EGFR) overexpression and the PI3K/AKT/mTOR pathway have shown efficacy. Additionally, immunotherapies targeting the PD-1/PD-L1 axis have demonstrated durable responses in advanced HNSCC. For thyroid cancer, BRAF V600E and RET/PTC rearrangements have been identified as potential therapeutic targets, with BRAF and RET inhibitors showing promising results. In salivary gland tumors, androgen receptor signaling and HER2 expression have emerged as potential targets for personalized treatment. Lymphomas of the neck have benefited from the use of anti-CD20 monoclonal antibodies and Bruton's tyrosine kinase inhibitors. Immunotherapy, particularly PD-1/PD-L1 blockade and adoptive cell therapy, has shown encouraging outcomes across various neck neoplasms. Combination therapies, such as concurrent chemoradiotherapy and targeted therapy with chemotherapy, have further improved treatment efficacy. However, challenges remain in identifying reliable biomarkers for predicting treatment response and overcoming resistance to cancer therapies. Ongoing clinical trials and research efforts are crucial for refining personalized treatment strategies and improving patient outcomes in neck neoplasms. • Advancements in targeted therapies and immunotherapy have revolutionized the treatment of head and neck cancers. • Precision medicine and immunotherapy have changed how neck cancer is treated by customizing treatments. • Neck tumors are built on a variety of different molecules and genetic changes. • The tumor microenvironment plays a big impact on how neck tumors grow and resist treatment. • Head and neck squamous cell carcinoma is highly responsive to personalized therapeutic approaches.

Authors

Institutions

Publication Details

Journal
Oral Oncology Reports
Published
2024-10-18
DOI
https://doi.org/10.1016/j.oor.2024.100669
Citations
1
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.29
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Precision oncology in head and neck cancers: From molecular mechanisms to novel therapeutic strategies

Karthikeyan Elumalai, M. Yuvaraj, S Madhumitha, D. Sakthi Sanjana et al.
1 citations
Oral Oncology Reports
Cancer Genomics and Diagnostics
0.29
article

Precision oncology in head and neck cancers: From molecular mechanisms to novel therapeutic strategies

Karthikeyan Elumalai, M. Yuvaraj, S Madhumitha, D. Sakthi Sanjana, E. Elizabeth Rani
article en
1 citations

Abstract

Neck neoplasms encompass a diverse group of malignancies, including head and neck squamous cell carcinoma (HNSCC), thyroid cancer, salivary gland tumors, and lymphomas. Recent advancements in molecular biology and immunotherapy have revolutionized the treatment landscape for these cancers. Personalized medicine, guided by genomic profiling and biomarker-driven therapies, has emerged as a promising approach to improve patient outcomes. In HNSCC, targeted therapies focusing on epidermal growth factor receptor (EGFR) overexpression and the PI3K/AKT/mTOR pathway have shown efficacy. Additionally, immunotherapies targeting the PD-1/PD-L1 axis have demonstrated durable responses in advanced HNSCC. For thyroid cancer, BRAF V600E and RET/PTC rearrangements have been identified as potential therapeutic targets, with BRAF and RET inhibitors showing promising results. In salivary gland tumors, androgen receptor signaling and HER2 expression have emerged as potential targets for personalized treatment. Lymphomas of the neck have benefited from the use of anti-CD20 monoclonal antibodies and Bruton's tyrosine kinase inhibitors. Immunotherapy, particularly PD-1/PD-L1 blockade and adoptive cell therapy, has shown encouraging outcomes across various neck neoplasms. Combination therapies, such as concurrent chemoradiotherapy and targeted therapy with chemotherapy, have further improved treatment efficacy. However, challenges remain in identifying reliable biomarkers for predicting treatment response and overcoming resistance to cancer therapies. Ongoing clinical trials and research efforts are crucial for refining personalized treatment strategies and improving patient outcomes in neck neoplasms. • Advancements in targeted therapies and immunotherapy have revolutionized the treatment of head and neck cancers. • Precision medicine and immunotherapy have changed how neck cancer is treated by customizing treatments. • Neck tumors are built on a variety of different molecules and genetic changes. • The tumor microenvironment plays a big impact on how neck tumors grow and resist treatment. • Head and neck squamous cell carcinoma is highly responsive to personalized therapeutic approaches.

Oral Oncology ReportsVol. 12
Saveetha University (IN)
Openalex Percentile: Top 38%
Cancer Genomics and Diagnostics
0.29
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.